Literature DB >> 2355883

Production of tumor necrosis factors by human T cell lines infected with HTLV-1 may cause their high susceptibility to human immunodeficiency virus infection.

N Kobayashi1, Y Hamamoto, N Yamamoto.   

Abstract

The production of tumor necrosis factor (TNF)-alpha and TNF-beta by various human hematopoietic cell lines was quantitatively examined using a highly sensitive radioimmunoassay specific to TNF-alpha, or a cytolytic assay performed with mouse L929 cells. It was found that the HTLV-1-infected T cell lines examined produced large amounts of both TNF-alpha and TNF-beta. In particular, interleukin-2 (IL-2)-dependent cell lines produced large amounts of TNF-alpha. In contrast, human cell lines not infected with HTLV-1 essentially did not produce either of the TNFs. It was also found that the high production of TNF-alpha by HTLV-1-infected cells partially correlated to their high sensitivity to human immunodeficiency virus (HIV) infection. Treatment of MT-4 cells, one of the most HIV-sensitive HTLV-1-infected cell lines, with antibody specific to TNF-alpha reduced their sensitivity to HIV infection.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2355883     DOI: 10.1007/bf00198532

Source DB:  PubMed          Journal:  Med Microbiol Immunol        ISSN: 0300-8584            Impact factor:   3.402


  24 in total

1.  Superinduction of trans-activation accounts for augmented human immunodeficiency virus replication in HTLV-I-transformed cells.

Authors:  T Okamoto; T Akagi; H Shima; M Miwa; K Shimotohno
Journal:  Jpn J Cancer Res       Date:  1987-12

2.  Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay.

Authors:  S Harada; Y Koyanagi; N Yamamoto
Journal:  Science       Date:  1985-08-09       Impact factor: 47.728

3.  Enhancement of HIV replication and giant cell formation by tumor necrosis factor.

Authors:  T Matsuyama; H Yoshiyama; Y Hamamoto; N Yamamoto; G Soma; D Mizuno; N Kobayashi
Journal:  AIDS Res Hum Retroviruses       Date:  1989-04       Impact factor: 2.205

4.  Evidence for aberrant activation of the interleukin-2 autocrine loop by HTLV-1-encoded p40x and T3/Ti complex triggering.

Authors:  M Maruyama; H Shibuya; H Harada; M Hatakeyama; M Seiki; T Fujita; J Inoue; M Yoshida; T Taniguchi
Journal:  Cell       Date:  1987-01-30       Impact factor: 41.582

5.  Cytocidal effect of tumor necrosis factor on cells chronically infected with human immunodeficiency virus (HIV): enhancement of HIV replication.

Authors:  T Matsuyama; Y Hamamoto; G Soma; D Mizuno; N Yamamoto; N Kobayashi
Journal:  J Virol       Date:  1989-06       Impact factor: 5.103

6.  Enhancement of human immunodeficiency virus production by natural lymphotoxin.

Authors:  T Matsuyama; Y Hamamoto; S Kobayashi; M Kurimoto; J Minowada; N Kobayashi; N Yamamoto
Journal:  Med Microbiol Immunol       Date:  1988       Impact factor: 3.402

7.  Tumor necrosis factor (TNF).

Authors:  L J Old
Journal:  Science       Date:  1985-11-08       Impact factor: 47.728

8.  Lymphocyte-activating and growth-inhibitory activities for several sources of native and recombinant interleukin 1.

Authors:  E V Gaffney; S C Tsai
Journal:  Cancer Res       Date:  1986-08       Impact factor: 12.701

9.  HTLV-1 transactivator induces interleukin-2 receptor expression through an NF-kappa B-like factor.

Authors:  K Leung; G J Nabel
Journal:  Nature       Date:  1988-06-23       Impact factor: 49.962

10.  Expression of different combinations of interleukins by human T cell leukemic cell lines that are clonally related.

Authors:  T Noma; H Nakakubo; M Sugita; S Kumagai; M Maeda; A Shimizu; T Honjo
Journal:  J Exp Med       Date:  1989-05-01       Impact factor: 14.307

View more
  1 in total

1.  Anti-Fas monoclonal antibody is cytocidal to human immunodeficiency virus-infected cells without augmenting viral replication.

Authors:  N Kobayashi; Y Hamamoto; N Yamamoto; A Ishii; M Yonehara; S Yonehara
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.